Wo2003077914a1 outlines the synthesis of binimetinib, a MEK inhibitor used in cancer treatment. The patent details a process involving several key steps to construct the molecule.
How is Binimetinib Synthesized According to Wo2003077914a1?
The synthesis described in Wo2003077914a1 involves preparing a key intermediate, 4-((4-amino-1,3-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-N-(2-hydroxyethyl)-N-methylbenzamide, and then reacting it with a halogenated derivative.
One synthetic route involves the preparation of 2,4-dichloro-1,3-dimethyl-1H-pyrazolo[3,4-d]pyrimidine. This intermediate is then reacted with 4-amino-N-(2-hydroxyethyl)-N-methylbenzamide to form a precursor. Subsequent steps, including potential protection and deprotection of functional groups, lead to the final binimetinib molecule [1].
What are the Key Intermediates in Binimetinib Synthesis?
Key intermediates identified in the patent include substituted pyrazolo[3,4-d]pyrimidines and aniline derivatives. For instance, 2,4-dichloro-1,3-dimethyl-1H-pyrazolo[3,4-d]pyrimidine serves as a crucial building block. Another important intermediate is 4-amino-N-(2-hydroxyethyl)-N-methylbenzamide [1].
When Does the Binimetinib Patent Expire?
The patent Wo2003077914a1 was filed on March 6, 2003, and published on September 25, 2003 [1]. Patent expiry dates can be complex, often involving extensions due to regulatory review periods. For the most accurate and up-to-date information on binimetinib patent expiry, consulting specialized patent databases is recommended. DrugPatentWatch.com provides detailed patent information, including expiry dates, for numerous pharmaceuticals [2].
What Other Patents Cover Binimetinib?
While Wo2003077914a1 covers the initial synthesis of binimetinib, additional patents may exist for improved synthesis methods, different formulations, or new uses of the drug. Pharmaceutical companies often file multiple patents throughout a drug's lifecycle to protect their intellectual property.
How does Binimetinib work as a MEK inhibitor?
Binimetinib functions by inhibiting the activity of MEK (mitogen-activated protein kinase kinase) enzymes. MEK is part of the RAS/RAF/MEK/ERK signaling pathway, which plays a critical role in cell growth, proliferation, and survival. In certain cancers, this pathway is hyperactivated, driving tumor development. By blocking MEK, binimetinib disrupts this signaling cascade, leading to reduced cancer cell proliferation and survival.
What is the Regulatory Status of Binimetinib?
Binimetinib, marketed as Mektovi, has received regulatory approval in several regions for the treatment of specific types of melanoma, often in combination with other targeted therapies like encorafenib. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have reviewed its efficacy and safety.
What are the Clinical Applications of Binimetinib?
Binimetinib is approved for use in patients with BRAF V600E or BRAF V600K mutations, a genetic alteration commonly found in melanoma. It is typically prescribed in combination with encorafenib, another targeted therapy, to treat unresectable or metastatic melanoma.
What are the Side Effects of Binimetinib?
Common side effects associated with binimetinib treatment, particularly when used in combination with encorafenib, can include gastrointestinal issues such as diarrhea, nausea, and vomiting. Other potential side effects may involve fatigue, skin reactions, and elevated liver enzymes. Patients are advised to discuss potential side effects with their healthcare provider.
What are the Alternatives to Binimetinib for Melanoma?
Treatment options for melanoma are varied and depend on the stage and genetic profile of the cancer. Alternatives to binimetinib-based therapy may include immunotherapy (e.g., checkpoint inhibitors), chemotherapy, and other targeted therapy combinations, depending on the presence of specific mutations like BRAF or PD-L1 expression.
Sources:
[1] WO2003077914A1. (2003). Pharmaceutical compounds. Retrieved from https://patents.google.com/patent/WO2003077914A1/en
[2] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/